U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709299) titled 'Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection' on June 30.
Brief Summary: This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of w...